NeuroOne Medical Technologies reported Q2 fiscal 2026 EPS of -$0.25, missing the forecast of -$0.22. Revenue came in at $2.4 million, below the expected $2.58 million.
Despite the misses, the stock rose 4.16% to $4.51, driven by investor optimism over strategic initiatives and product innovations. Product revenue surged 72% YoY, led by the OneRF Brain Ablation System.
The company completed Stage 2 ISO 13485 audit, paving the way for international distribution. CEO Dave Rosa expressed confidence in the pipeline and strategic direction.
